Circulating Immune Markers for Prognostic Evaluation in Postoperative Lung Cancer Patients

Condition(s) studied

Investigational drug(s) / intervention(s)

Preoperative Peripheral Blood Immune Marker Analysis.: Preoperative collection of approximately 5 mL peripheral blood via venipuncture, followed by isolation of peripheral blood mononuclear cells (PBMCs) using Ficoll density gradient centrifugation. PBMCs are analyzed via multiparametric flow cytometry on a BD FACSCanto II system to quantify antigen-specific effector T cells (ETASTs, co-expressing CD137 and IFN-γ after ex vivo stimulation with NSCLC antigen peptide pools like NY-ESO-1 and MAGE-A3) and the effector T cell to regulatory T cell ratio (Teff/Treg, with Teff as CD4+/CD8+ expressing IFN-γ/TNF-α/IL-2 and Treg as CD4+CD25+FoxP3+). Analysis uses FlowJo software, targeting 100,000 events per sample. This non-invasive prognostic assessment is distinct from routine clinical blood tests by its focus on tumor-specific immune activation and balance, without therapeutic intent or alteration of standard care.

Study summary

Investigating the Clinical Value of Tumor Antigen-Specific T Cells and Immune Cell Balance in Peripheral Blood of Non-Small Cell Lung Cancer Patients for Prognostic Evaluation.

Eligibility

Primary outcome measure(s)

• Recurrence-Free Survival — 3 years postoperatively
  The time from the date of surgery to the first occurrence of disease recurrence, metastasis, or death from any cause.

Trial sites (1)

More Zhao Jun trials in China

Other trials for the same condition